These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

716 related items for PubMed ID: 17145859

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.
    Teofili L, Giona F, Martini M, Cenci T, Guidi F, Torti L, Palumbo G, Amendola A, Foà R, Larocca LM.
    J Clin Oncol; 2007 Mar 20; 25(9):1048-53. PubMed ID: 17369568
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. HLA-G turns off erythropoietin receptor signaling through JAK2 and JAK2 V617F dephosphorylation: clinical relevance in polycythemia vera.
    Menier C, Guillard C, Cassinat B, Carosella ED, Rouas-Freiss N.
    Leukemia; 2008 Mar 20; 22(3):578-84. PubMed ID: 18059484
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Histological and molecular classification of chronic myeloproliferative disorders in the age of JAK2: persistence of old questions despite new answers.
    Hussein K, Bock O, Kreipe H.
    Pathobiology; 2007 Mar 20; 74(2):72-80. PubMed ID: 17587878
    [Abstract] [Full Text] [Related]

  • 30. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
    Michiels JJ, Berneman Z, Van Bockstaele D, van der Planken M, De Raeve H, Schroyens W.
    Semin Thromb Hemost; 2006 Apr 20; 32(3):174-207. PubMed ID: 16673274
    [Abstract] [Full Text] [Related]

  • 31. Elevated serum erythropoietin levels in patients with Budd-Chiari syndrome secondary to polycythemia vera: clinical implications for the role of JAK2 mutation analysis.
    Thurmes PJ, Steensma DP.
    Eur J Haematol; 2006 Jul 20; 77(1):57-60. PubMed ID: 16827884
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Bone marrow mesenchymal stromal cells of patients with myeloproliferative disorders do not carry the JAK2-V617F mutation.
    Mercier F, Monczak Y, François M, Prchal J, Galipeau J.
    Exp Hematol; 2009 Mar 20; 37(3):416-20. PubMed ID: 19135773
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Telomere shortening in Ph-negative chronic myeloproliferative neoplasms: a biological marker of polycythemia vera and myelofibrosis, regardless of hydroxycarbamide therapy.
    Ruella M, Salmoiraghi S, Risso A, Carobbio A, Buttiglieri S, Spatola T, Sivera P, Ricca I, Barbui T, Tarella C, Rambaldi A.
    Exp Hematol; 2013 Jul 20; 41(7):627-34. PubMed ID: 23542632
    [Abstract] [Full Text] [Related]

  • 40. [Essential thrombocythemia. Contribution of the V617F JAK2 mutation to the pathophysiology, diagnosis and outcome].
    Brière J.
    Bull Acad Natl Med; 2007 Mar 20; 191(3):535-48. PubMed ID: 18072652
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 36.